Drugs / GS-0272
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06031415 | Sep 2023 → May 2026 | rheumatoid arthritis | Gilead Sciences | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-0272 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06031415 ↗ |
| Route | Subcutaneous | “Administered subcutaneously” NCT06031415 ↗ |